ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lonza will expand its viral-based therapeutics business with the construction of a clean room at its Houston facility. To open early next year, the clean room will house disposable bioreactors of up to 2,000 L that support late-stage viral vaccine and gene therapy projects. Lonza entered viral manufacturing in August 2010 through the acquisition of Houston-based Vivante GMP Solutions. The Swiss firm says viral vaccines are cheaper to make than traditional egg-based vaccines.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter